[402] NON-INVASIVE PROCEDURE FOR INTERVENTIONAL PAIN MANAGMENT TREATMENT

Ron Aginsky[1], Arik Hananel[2], [1] President, Fusmobile Inc., [2] CEO, Fusmobile Inc.

FUSMobile's device, the Neurolyser, provides a better therapeutic solution to alleviate chronic pain in a noninvasive manner, using High Intensity Focused Ultrasound (HIFU). A pilot study evaluating safety and initial effectiveness was completed in Canada with promising initial results. FUSMobile has partnered with luminaries in the field of HIFU and interventional pain management. Its founders and team have extensive experience in the medical device field.

FUSMobile's first indication is the treatment of chronic low back pain caused by arthritis of the vertebra's facet joint, a condition that affects millions of patients and is the most common cause for opioid addiction. FUSMobile technology provides the interventional pain market a better therapeutic solution, superior patient experience and is reducing costs for healthcare providers and payers. The company revenue comprises of selling the device, consumables and service to interventional pain clinicians.

The Neurolyser's is an image guided HIFU platform, optimized for thermal ablation of soft tissue at the bone tissue interface. Its noninvasive nature offers procedural comfort for the patient and eliminates the risks of infection and bleeding. Additionally, the Neurolyser has substantially lower logistical complexity and operational costs compared to other stand of care procedures.

A pilot study for treatment of facet arthritis low back pain was completed in Canada. FUSMobile is launching its next clinical studies to expedite its' time to market. The interventional pain management market is rapidly growing and is estimated to be around $1Bm. Large healthcare companies are active in this market with number of M&A transactions and recent new products launches. FUSMobile targets regulatory approval in Canada and FDA 510K de-novo clearance for low back pain as first indication.

FUSMobile is currently raising funds to support its phase 3 study as well as expanding the Neurolyser platform for additional indications and imaging modalities.